Shares of Novavax Inc (NASDAQ:NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers and the broader biotechnology sector.

Merck-Moderna Clinical Breakthrough Triggers Industry-Wide Momentum

The catalyst lifting Novavax stems from landmark Phase 3 INTerpath-001 trial results released Wednesday by Merck & Co Inc and Moderna Inc. The partners announced that their individualized mRNA cancer vaccine, intismeran autogene, combined with Keytruda significantly improved recurrence-free survival in advanced melanoma patients.

The historical readout, representing the first positive Phase 3 win for a custom cancer therapy, ignited a massive risk-on rally across the biopharmaceutical space. The SPDR S&P Biotech ETF (NYSE:XBI) spiked more than 4% early Wednesday, lifting pure-play vaccine makers alongside drug developers.

Adjuvant Platform and Sector Re-Rating Support Novavax Rally

While Novavax is traditionally recognized for its protein-based infectious disease vaccines, the late-stage validation of complex therapeutic vaccines highlights the growing industry importance of advanced delivery systems.

Novavax continues to market its proprietary Matrix-M saponin-based adjuvant platform, which enhances immune responses and remains a key asset for potential partner licensing in oncology and respiratory combination pipelines.

NVAX Shares Climb Wednesday Afternoon

NVAX Price Action: Novavax shares were up 5.17% at $8.34 at the time of publication on Wednesday, according to Benzinga Pro data.

Read Also: Treasury Just Doubled Its Bond Buybacks: What That Can and Can't Fix

Image: Shutterstock